Autolane | $7,400,000 | (Dec 4, 2025)
Curvestone AI | $4,000,000 | (Dec 4, 2025)
Ridley | $6,400,000 | (Dec 4, 2025)
Certified by Founder
Lodge
OrsoBio
start up
United States
- Palo Alto, CA
- 08/11/2023
- Series A
- $60,000,000
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- Industry Biotechnology Research
- Website https://orsobio.com/
- LinkedIn https://www.linkedin.com/company/orsobio/about/
Track Titan | $5,000,000 | (Dec 4, 2025)
Curi Bio | $10,000,000 | (Dec 4, 2025)
Unacast | $28,000,000 | (Dec 4, 2025)
Fin | $17,000,000 | (Dec 4, 2025)
Supper | $11,000,000 | (Dec 4, 2025)
Gradium | $70,000,000 | (Dec 4, 2025)
Juniper Biosciences | $40,000,000 | (Dec 4, 2025)
Heven AeroTech | $100,000,000 | (Dec 4, 2025)
PineAI | $25,000,000 | (Dec 4, 2025)